On 4/5/24, Marinus Pharmaceuticals Inc (NASDAQ: MRNS) stock suffered a major decline of -10.1%, closing at $7.80. Moreover, this decline was accompanied by exceptionally high trading volume at 200% of normal. The stock has declined -11.9% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, MRNS is expected to continue to be a modest Value Eraser.
Marinus Pharmaceuticals has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Marinus Pharmaceuticals has a very low Appreciation Score of 1 but a slightly positive Power Rating of 70, and the Negative Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment